AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy. (March 2018) - Schindler, U.; Seitz, L.; Ashok, D.; Piovesan, D.; Tan, J.; DiRenzo, D.; Yin, F.; Leleti, M.; Rosen, B.; Miles, D.; Jin, L.; Park, T.; et al.